Genzyme Rare-Disease Drug Denied Accelerated Decision by FDA

Genzyme and its partner Isis Pharmaceuticals said the U.S. Food and Drug Administration accepted their potential treatment for a rare, genetic form of extremely high cholesterol for review, after it was initially sent to the agency in March.
Boston Business Journals